The efficacy of isotretinoin plus NB-UVB in the treatment of psoriasis vulgaris
Phase 2
- Conditions
- Psoriasis vulgaris.psoriasis vulgaris
- Registration Number
- IRCT138812213543N1
- Lead Sponsor
- Behestan Darou (P.J.S)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Patients with chronic plaque type psoriasis (psoriasis vulgaris) who are candidates for phototherapy
Exclusion criteria: female patients who do not have a safe contraception or want to become pregnant in less than 1 month, patient with abnormal lipid profile tests, liver function tests and ANA
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement of severity of psoriasis vulgaris. Timepoint: First visit, 4 weeks, 10 weeks, 14 weeks after starting therapy. Method of measurement: PASI score.
- Secondary Outcome Measures
Name Time Method Complications (nausea, pruritus, erythrodermia). Timepoint: First visit, 4 weeks, 10 weeks, and 14 weeks after starting therapy. Method of measurement: clinical examination.